These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2323301

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M, Odermatt B, Christen B, Rüttner JR.
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [Abstract] [Full Text] [Related]

  • 5. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE, Lucas JG, Bucci DM, Schlom J, Primus J.
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [Abstract] [Full Text] [Related]

  • 6. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW.
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [Abstract] [Full Text] [Related]

  • 7. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M, Hoogsteden HC, Van der Kwast TH.
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T.
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
    Pu RT, Pang Y, Michael CW.
    Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T, Greenberg SD, Truong LD, Mattioli CA, Klima M, Titus JL.
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.
    Törrönen K, Soini Y, Pääkkö P, Parkkinen J, Sironen R, Rilla K.
    Histol Histopathol; 2016 Oct; 31(10):1113-22. PubMed ID: 26912058
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.
    Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I, Willingham MC.
    Am J Surg Pathol; 1992 Mar; 16(3):259-68. PubMed ID: 1599018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.